Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250788 | 1.00 | TDP1 (0.33) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL3290225 | 0.89 | BHMT (0.37) | TDP1EYA2APPACEALOX15 | |
| SCHEMBL3290209 | 0.89 | BHMT (0.37) | TDP1EYA2APPACEALOX15 | |
| SCHEMBL9889117 | 0.84 | RNPEP (0.33) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL5590884 | 0.81 | CYP2D6 (0.42) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL13090504 | 0.77 | — | — | |
| SCHEMBL22313 | 0.76 | TDP1 (0.42) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL1707477 | 0.76 | TDP1 (0.42) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL652071 | 0.76 | TDP1 (0.36) | TDP1EYA2APPACECYP2C19 | |
| SCHEMBL652072 | 0.76 | TDP1 (0.36) | TDP1EYA2APPACECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7988858-B2 | Method for generating metal chelating affinity ligands | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-7709612-B2 | Metal chelating compositions for protein purification, detection or binding | SIGMA-ALDRICH CO. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090200239-A1 | METHOD FOR GENERATING METAL CHELATING AFFINITY LIGANDS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2009-08-13 | — | — | US | disclosed |
| EP-1276716-B2 | METAL CHELATING COMPOSITIONS | SIGMA ALDRICH CO (US) | 2008-10-01 | — | — | EP | disclosed |
| US-7175767-B2 | Preparation of a metal chelating separation medium | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199950-A1 | Preparation of a metal chelating separation medium | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2006-09-07 | — | — | US | disclosed |
| US-20060148090-A1 | Metal chelating compositions for protein purification, detection or binding | SIGMA-ALDRICH CO. (US) | 2006-07-06 | — | — | US | disclosed |
| US-7033520-B2 | Metal chelating compositions for protein purification, detection or binding | SIGMA-ALDRICH CO. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1627683-A2 | Metal chelating compositions | Sigma Aldrich Company (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1276716-B1 | METAL CHELATING COMPOSITIONS | SIGMA ALDRICH CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040092031-A1 | Metal chelating compositions for protein purification, detection or binding | SIGMA - ALDRICH CO. | 2004-05-13 | — | — | US | disclosed |
| US-6623655-B1 | Nitrilotriacetic acid derivatives; improved specificity and stability; protein purification, detection and/or binding | SIGMA-ALDRICH CO. | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090200239-A1 | METHOD FOR GENERATING METAL CHELATING AFFINITY LIGANDS | SPR, SPEN, TIMCC | TDP1 4850/4885EYA2 3839/4885APP 1595/4885 |
| US-20060199950-A1 | Preparation of a metal chelating separation medium | CA1, CA3, CA12 | TDP1 4195/4885EYA2 3071/4885APP 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.